Shares of Cytosorbents Corp (NASDAQ:CTSO) have received a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $15.00.
A number of analysts have recently weighed in on CTSO shares. HC Wainwright upped their price target on shares of Cytosorbents from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Maxim Group started coverage on shares of Cytosorbents in a research note on Thursday, May 7th. They issued a “buy” rating and a $14.00 price target for the company. B. Riley reaffirmed a “buy” rating on shares of Cytosorbents in a research note on Thursday, July 23rd. ValuEngine lowered shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, BidaskClub raised shares of Cytosorbents from a “hold” rating to a “buy” rating in a research note on Tuesday, June 30th.
Cytosorbents stock opened at $9.58 on Friday. The company has a quick ratio of 3.10, a current ratio of 3.27 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average price of $9.81 and a two-hundred day moving average price of $7.68. The firm has a market capitalization of $346.72 million, a price-to-earnings ratio of -17.41 and a beta of 0.57. Cytosorbents has a 52-week low of $3.49 and a 52-week high of $11.74.
Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Tuesday, May 5th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $8.71 million during the quarter, compared to analyst estimates of $7.14 million. Cytosorbents had a negative net margin of 62.65% and a negative return on equity of 165.86%. Research analysts expect that Cytosorbents will post -0.36 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG raised its stake in shares of Cytosorbents by 74.2% in the 4th quarter. UBS Group AG now owns 43,015 shares of the medical research company’s stock valued at $166,000 after buying an additional 18,326 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Cytosorbents by 207.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 41,499 shares of the medical research company’s stock valued at $160,000 after buying an additional 27,985 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Cytosorbents by 5.7% in the 4th quarter. Bank of New York Mellon Corp now owns 120,681 shares of the medical research company’s stock valued at $465,000 after buying an additional 6,540 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Cytosorbents by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 359,652 shares of the medical research company’s stock valued at $1,384,000 after buying an additional 6,891 shares in the last quarter. Finally, Cypress Capital Group acquired a new stake in shares of Cytosorbents during the 1st quarter worth about $139,000. 27.46% of the stock is owned by institutional investors and hedge funds.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Further Reading: What is the Euro STOXX 50 Index?
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.